<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">91414</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Eritropoetin: primenenie na ranney i dializnoy stadiyakh khronicheskoy pochechnoy nedostatochnosti</article-title><trans-title-group xml:lang="ru"><trans-title>Эритропоэтин: применение на ранней и диализной стадиях хронической почечной недостаточности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nikolaev</surname><given-names>A. Yu</given-names></name><name xml:lang="ru"><surname>Николаев</surname><given-names>А. Ю</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нефрологии ФППО ММА им. И.М.Сеченова</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlovskaya</surname><given-names>L. V</given-names></name><name xml:lang="ru"><surname>Козловская</surname><given-names>Л. В</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нефрологии ФППО ММА им. И.М.Сеченова</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ММА им. И.М.Сеченова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2001-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2001</year></pub-date><volume>3</volume><issue>7</issue><issue-title xml:lang="en">VOL 3, NO7 (2001)</issue-title><issue-title xml:lang="ru">ТОМ 3, №7 (2001)</issue-title><fpage>339</fpage><lpage>342</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2001, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2001, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2001</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/91414">https://consilium.orscience.ru/2075-1753/article/view/91414</self-uri><abstract xml:lang="ru"><p>Анемия является одним из серьезных осложнений, определяющих качество жизни и выживаемость больных хроническими заболеваниями почек на стадии хронической почечной недостаточности (ХПН). Препараты эпоэтина как средство патогенетической заместительной терапии существенно увеличивают выживаемость и повышают качество жизни больных ХПН. Безопасность и эффективность лечения эпоэтином определяется правильностью выбора дозы препарата, целевого Hb (Ht), адекватностью контроля за гипертонией, скоростью прироста Hb (Ht) и балансом железа в организме больного.</p></abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Levin A, Thompson C.R, Ethier J. Am J Kidney Dis 1999; 34: 125-34.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Greaves S.C, Gamble G.D, Collins J.F. et al. Tbit 1994; 24: 768-76.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Foley R.N, Parfrey P.S, Harnett J.D. Tbit 1996; 28: 53-61.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Eknoyan G. Electrolyte Metab 1999; 25: 100-4.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Harnett L.D, Foley R.N, Kent G.M. et al. Kidney Int 1995; 47: 884-90.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Weiss L.G, Clyne N, Fihlho J.D et al. The efficacy of one weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicenter trial. Nephrol Dial transplant 2000; 15:2014-19.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ермоленко В.М. Состояние сердечно - сосудистой системы при ХПН. В: С.И.Рябов (ред). Лечение хронической почечной недостаточности. Спб.: ИКФ "Фолиант", 1997; 163-75.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Алексеева Т.А., Николаев А.Ю. Тер. арх. 2000; 6: 58-60.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Eckardt K.U. Nephrol Dial Transplant 1999; 14: 1317-23.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wizemann V, Kaufmann J, Kramer W. Nephron 1992; 62: 151-65.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>European best practice guidelines for the management of anaemia in patrients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (Suppl. 5): 1-50.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Besarab A, Levin A. Am J Kidney Dis 2000; 36 (Suppl. 3): 13-23.</mixed-citation></ref></ref-list></back></article>
